{"id":"W4402354861","doi":"10.3310/jwtr4127","title":"Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT","year":2024,"lang":"en","type":"article","venue":"Health Technology Assessment","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Programme Grants for Applied Research; Health Technology Assessment Programme; British Society of Interventional radiology; International Network of Agencies for Health Technology Assessment; Ipsen; European School of Oncology; Department of Health and Social Care; University of Leeds; National Institute for Health and Care Research; Bowel Cancer UK; British Heart Foundation; Engineering and Physical Sciences Research Council; AstraZeneca; National Cancer Research Institute; Cancer Research UK; Boston Scientific Corporation; GlaxoSmithKline; Amgen","keywords":"Medicine; Internal medicine; Sunitinib; Randomized controlled trial; Quality of life (healthcare); Confidence interval; Pazopanib; Intention-to-treat analysis; Renal cell carcinoma; Oncology; Surgery","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01585423,0.001281265,0.003984745,0.0006332887,0.0005727322,0.00202776,0.0008692436,0.002794506,0.01213742],"category_scores_gemma":[0.02155354,0.0005841316,0.007483725,0.0007400834,0.001490403,0.002094774,0.001164126,0.004640172,0.001006185],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162126,"about_ca_system_score_gemma":0.001774581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001000881,"about_ca_topic_score_gemma":0.001463398,"domain_scores_codex":[0.9846049,0.01219515,0.001380703,0.0008221751,0.0005262929,0.0004707789],"domain_scores_gemma":[0.9809616,0.01121754,0.004639542,0.001381913,0.0008229304,0.0009764067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9373322,0.001751599,0.001366731,0.01149348,0.01413003,0.00005307925,0.0002151041,0.0004134387,0.0006061412,0.0008415819,0.001459853,0.03033677],"study_design_scores_gemma":[0.9310267,0.04715896,0.003281919,0.002084068,0.01067336,0.00007407982,0.0001381878,0.000539521,0.0003156478,0.00177887,0.002889403,0.00003930959],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8319721,0.1037064,0.008088307,0.006586114,0.003960146,0.02640748,0.003537397,0.0004076511,0.01533445],"genre_scores_gemma":[0.963952,0.01012295,0.005104533,0.002721696,0.001092908,0.01388821,0.0007871864,0.0000469716,0.002283507],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01585423,"threshold_uncertainty_score":0.08384621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02563838062294782,"score_gpt":0.3444084198598867,"score_spread":0.3187700392369389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}